Home CA125 reference values change in male and postmenopausal female subjects
Article
Licensed
Unlicensed Requires Authentication

CA125 reference values change in male and postmenopausal female subjects

  • Giuseppe Cartei , Francesco Cartei , Martina Bertin , Andrea Padoan EMAIL logo , Fable Zustovich , Maria Ornella Nicoletto and Mario Plebani
Published/Copyright: September 25, 2012
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 51 Issue 2

Abstract

Background: In cancer patients, including women with a diagnosis of ovarian cancer, cancer antigen 125 (CA125) is used to evaluate the presence of peritoneal involvement. The aims of the present study were to assess CA125 reference intervals and reference change values (RCV) in postmenopausal reference women, postmenopausal women breast cancer free, reference men and cancer free men.

Methods: The series consisted of 433 subjects: 105 postmenopausal breast cancer free women and 56 cancer free men in addition to a total of 272 reference subjects (145 postmenopausal women and 127 men). Repeated CA125 measurements were made in a subset of 149 women and 54 men to calculate RCV and index of individuality. Serum CA125 levels were evaluated by a chemiluminescent assay.

Results: In postmenopausal reference women, the mean CA125 value and 2.5th–97.5th percentiles were 6.70, 2.60–11.00 kU/L, respectively, with a unidirectional RCV of 38.4%. In postmenopausal breast cancer free women, the mean CA125 value and 2.5th–97.5th percentile were 7.45, 4.09–10.92 kU/L, respectively, with a RCV of 34.5%. The difference between the means was statistically significant (t=–3.02, p=0.003). In the two male subgroups, the difference between the means for CA125 was not statistically significant (t=0.43, p=0.665). On considering the entire male population, the mean CA125 value and 2.5th–97.5th percentiles were 7.50 and 2.40–13.2 kU/L, respectively, while the unidirectional RCV was 34.3%. In all the studied groups, the indices of individuality were equal to or below 0.6.

Conclusions: The extremely low index of individuality found underlines the importance of using the RCV instead of absolute values as a parameter when interpreting the CA125 data in the monitoring and follow-up of patients with ovarian cancer.

Keywords: CA125 antigen; index of individuality; ovarian cancer; postmenopausal women; reference change values; reference values
Corresponding author: Andrea Padoan, Department of Laboratory Medicine, University-Hospital of Padua, via Giustiniani 2, 35128 Padua, Italy, Phone: +39 49 8212801, Fax: +39 49 8211981

The authors wish to thank Giovanni Minervini and Emanuele Argese, Department of Environmental Sciences, Ca’ Foscari University of Venice, for their preliminary analyses, and Antonino Abrami, Venice Court of Appeal Judge and former holder of the European “Jean Monnet” Chair at the University of Urbino, for his legal advice.

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

References

1. Bischof P. What do we know about the origin of CA 125? Eur J Obstet Gynecol Reprod Biol 1993;49:93–8.10.1016/0028-2243(93)90131-USearch in Google Scholar

2. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883–7.10.1056/NEJM198310133091503Search in Google Scholar PubMed

3. Mastropaolo W, Fernandez Z, Miller EL. Pronounced increases in the concentration of an ovarian tumor marker. Clin Chem 1986;11:2110–11.10.1093/clinchem/32.11.2110Search in Google Scholar

4. Maggino T, Gadducci A, D’Addario V, Pecorelli S, Lissoni A, Stella M, et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994;54:117–23.10.1006/gyno.1994.1179Search in Google Scholar PubMed

5. Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res 2011;4:1401–8.10.1158/1940-6207.CAPR-10-0402Search in Google Scholar PubMed PubMed Central

6. Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009;9:555–66.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000270189800004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1586/erm.09.39Search in Google Scholar PubMed PubMed Central

7. Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 2009;23:331–5.10.1002/jcla.20340http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000270602800006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed PubMed Central

8. Lenhard M, Stieber P, Hertlein L, Kirschenhofer A, Fürst S, Mayr D, et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med 2011;49:2081–8.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000299856700023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1515/CCLM.2011.709Search in Google Scholar PubMed

9. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402–8.10.1016/j.ygyno.2007.10.017http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000253248700024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed

10. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40–6.10.1016/j.ygyno.2008.08.031Search in Google Scholar PubMed PubMed Central

11. Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011;49:521–5.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000288238500022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar

12. Park Y, Kim Y, Lee EY, Lee JH, Kim HS. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer 2012;130:1136–44.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000298601500016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1002/ijc.26129Search in Google Scholar

13. Tortolero-Luna G, Mitchell MF. The epidemiology of ovarian cancer. J Cell Biochem Suppl 1995;23:200–7.10.1002/jcb.240590927Search in Google Scholar

14. Sugishita K, Kashiwagi A, Nagamori S, Yamashiro K, Sato N. Serous papillary adenocarcinoma of the tunica vaginalis of the testis: a case report. Nihon Hinyokika Gakkai Zasshi 2004;95:626–9.10.5980/jpnjurol1989.95.626Search in Google Scholar

15. Jones MA, Young RH, Srigley JR, Scully RE. Paratesticular serous papillary carcinoma. A report of six cases. Am J Surg Pathol 1995;19:1359–65.10.1097/00000478-199512000-00003Search in Google Scholar PubMed

16. Thiel R, Effert P. Primary adenocarcinoma of the seminal vesicles. J Urol 2002;168:1891–6.10.1016/S0022-5347(05)64260-7Search in Google Scholar

17. O’Brien TJ, Hardin JW, Bannon GA, Norris JS, Quirk JG Jr. CA 125 antigen in human amniotic fluid and fetal membranes. Am J Obstet Gynecol 1986;155:50–5.10.1016/0002-9378(86)90076-1Search in Google Scholar

18. Matorras R, Genollá J, Corcóstegui B, Fraca M, Fombellida JC, Rodríguez-Escudero FJ. Human seminal plasma analysis of five tumor markers: CA 125, alpha-fetoprotein, CA 50, CA 19.9, and CA 195. Int J Fertil Menopausal Stud 1994;39:223–8.Search in Google Scholar

19. Cramer DW, Vitonis AF, Welch WR, Terry KL, Goodman A, Rueda BR, et al. Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecol Oncol 2010;119:462–8.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000284556800012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.ygyno.2010.08.028Search in Google Scholar PubMed PubMed Central

20. Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003;10:150–4.10.1245/ASO.2003.05.015Search in Google Scholar

21. Bergamaschi S, Morato E, Bazzo M, Neves F, Fialho S, Castro G, et al. Tumor markers are elevated in patients with rheumatoid arthritis and do not indicate presence of cancer. Int J Rheum Dis 2012;15:179–82.10.1111/j.1756-185X.2011.01671.xSearch in Google Scholar PubMed

22. Yang Z, Liang Y, Li C, Zhong R. Serum CA125 elevation is independently associated with serositis in SLE patients. Clin Exp Rheumatol 2012;30:93–8.Search in Google Scholar

23. Morris PG, Swords R, Sukor S, Fortune A, O’Donnell DM, Conneally E. Autoimmune hemolytic anemia associated with ovarian cancer. J Clin Oncol 2008;26:4993–5.10.1200/JCO.2008.17.1231http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000260113600026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed

24. Christoforidis A, Lefkou E, Vlachaki E, Perifanis V, Tsatra I, Dogramatzi F, et al. Evaluation of serum tumour markers concentrations in patients with homozygous beta-thalassaemia in relation to demographical, clinical and biochemical parameters. Ann Hematol 2007;86:837–41.10.1007/s00277-007-0348-9http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000249777300009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed

25. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409–37.10.3109/10408368909106595Search in Google Scholar PubMed

26. Takami M, Sakamoto H, Ohtani K, Takami T, Satoh K. An evaluation of CA125 levels in 291 normal postmenopausal and 20 endometrial adenocarcinoma-bearing women before and after surgery. Cancer Lett 1997;121:69–72.10.1016/S0304-3835(97)00332-7Search in Google Scholar

27. Kurihara T, Mizunuma H, Obara M, Andoh K, Ibuki Y, Nishimura T. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma. Gynecol Oncol 1998;69:192–6.10.1006/gyno.1998.5018Search in Google Scholar PubMed

28. Plebani M, Melichar B. ROMA or death: advances in epithelial ovarian cancer diagnosis. Clin Chem Lab Med 2011;49:443–5.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000288238500012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed

29. Bjerner J, Høgetveit A, Wold Akselberg K, Vangsnes K, Paus E, Bjøro T, et al. Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study. Scand J Clin Lab Invest 2008;68:703–13.10.1080/00365510802126836Search in Google Scholar PubMed

30. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:489–93.Search in Google Scholar

31. Barceló B, Ayllón O, Belmonte M, Barceló A, Vidal R, Forteza-Rey J, et al. Proposed reference value of the CA 125 tumour marker in men. Potential applications in clinical practice. Clin Biochem 2008;41:717–22.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000256240100012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.clinbiochem.2008.02.016Search in Google Scholar PubMed

32. Tuxen MK, Sölétormos G, Petersen PH, Schioler V, Dombernowsky P. Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer. Gynecol Oncol 1999;74:12–22.10.1006/gyno.1999.5414Search in Google Scholar PubMed

33. Trapé J, Filella X, Alsina-Donadeu M, Juan-Pereira L, Bosch-Ferrer Á, Rigo-Bonnin R. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 2011;49:1605–20.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000296591500004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed

Received: 2012-06-28
Accepted: 2012-08-26
Published Online: 2012-09-25
Published in Print: 2013-02-01

©2013 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Letters to the Editor
  2. Performance evaluation of three different immunoassays for detection of antibodies to hepatitis B core
  3. Serum homocysteine concentrations in Chinese children with autism
  4. Interchangeability of venous and capillary HbA1c results is affected by oxidative stress
  5. Interference of hemoglobin (Hb) N-Baltimore on measurement of HbA1c using the HA-8160 HPLC method
  6. First human isolate of Mycobacterium madagascariense in the sputum of a patient with tracheobronchitis
  7. Protein S and protein C measurements should not be undertaken during vitamin K antagonist therapy
  8. α2-HS glycoprotein is an essential component of cryoglobulin associated with chronic hepatitis C
  9. An unusual interference in CK MB assay caused by a macro enzyme creatine phosphokinase (CK) type 2 in HIV-infected patients
  10. An automated technique for the measurement of the plasma glutathione reductase activity and determination of reference limits for a healthy population
  11. Is osteopontin stable in plasma and serum?
  12. Evidence-based approach to reducing perceived wasteful practices in laboratory medicine
  13. Masthead
  14. Masthead
  15. Editorials
  16. Testing volume is not synonymous of cost, value and efficacy in laboratory diagnostics
  17. Lessons from controversy: biomarkers evaluation
  18. Commercial immunoassays in biomarkers studies: researchers beware!1)
  19. Trials and tribulations in lupus anticoagulant testing
  20. Reviews
  21. Mass spectrometry: a revolution in clinical microbiology?
  22. Chronic Chagas disease: from basics to laboratory medicine
  23. General Clinical Chemistry and Laboratory Medicine
  24. Shop for quality or quantity? Volumes and costs in clinical laboratories
  25. Minor improvement of venous blood specimen collection practices in primary health care after a large-scale educational intervention
  26. Evaluation of high resolution gel β2-transferrin for detection of cerebrospinal fluid leak
  27. Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease
  28. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission
  29. Bone mass density selectively correlates with serum markers of oxidative damage in post-menopausal women
  30. Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma
  31. Performance of different screening methods for the determination of urinary glycosaminoclycans
  32. Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnosis tools for digestive non-IgE-mediated cow’s milk allergy in toddlers
  33. An internal validation approach and quality control on hematopoietic chimerism testing after allogeneic hematopoietic cell transplantation
  34. Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors
  35. Cooperation experience in a multicentre study to define the upper limits in a normal population for the diagnostic assessment of the functional lupus anticoagulant assays
  36. Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure
  37. Suitability of POC lactate methods for fetal and perinatal lactate testing: considerations for accuracy, specificity and decision making criteria
  38. Point-of-care testing on admission to the intensive care unit: lactate and glucose independently predict mortality
  39. Reference Values and Biological Variations
  40. CA125 reference values change in male and postmenopausal female subjects
  41. Distributions and ranges of values of blood and urinary biomarker of inflammation and oxidative stress in the workers engaged in office machine manufactures: evaluation of reference values
  42. Cancer Diagnostics
  43. Association of acute phase protein-haptoglobin, and epithelial-mesenchymal transition in buccal cancer: a preliminary report
  44. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients
  45. Evaluation of the BRAHMS Kryptor® Thyroglobulin Minirecovery Test in patients with differentiated thyroid carcinoma
https://doi.org/10.1515/cclm-2012-0414
Keywords for this article
CA125 antigen; index of individuality; ovarian cancer; postmenopausal women; reference change values; reference values

Articles in the same Issue

  1. Letters to the Editor
  2. Performance evaluation of three different immunoassays for detection of antibodies to hepatitis B core
  3. Serum homocysteine concentrations in Chinese children with autism
  4. Interchangeability of venous and capillary HbA1c results is affected by oxidative stress
  5. Interference of hemoglobin (Hb) N-Baltimore on measurement of HbA1c using the HA-8160 HPLC method
  6. First human isolate of Mycobacterium madagascariense in the sputum of a patient with tracheobronchitis
  7. Protein S and protein C measurements should not be undertaken during vitamin K antagonist therapy
  8. α2-HS glycoprotein is an essential component of cryoglobulin associated with chronic hepatitis C
  9. An unusual interference in CK MB assay caused by a macro enzyme creatine phosphokinase (CK) type 2 in HIV-infected patients
  10. An automated technique for the measurement of the plasma glutathione reductase activity and determination of reference limits for a healthy population
  11. Is osteopontin stable in plasma and serum?
  12. Evidence-based approach to reducing perceived wasteful practices in laboratory medicine
  13. Masthead
  14. Masthead
  15. Editorials
  16. Testing volume is not synonymous of cost, value and efficacy in laboratory diagnostics
  17. Lessons from controversy: biomarkers evaluation
  18. Commercial immunoassays in biomarkers studies: researchers beware!1)
  19. Trials and tribulations in lupus anticoagulant testing
  20. Reviews
  21. Mass spectrometry: a revolution in clinical microbiology?
  22. Chronic Chagas disease: from basics to laboratory medicine
  23. General Clinical Chemistry and Laboratory Medicine
  24. Shop for quality or quantity? Volumes and costs in clinical laboratories
  25. Minor improvement of venous blood specimen collection practices in primary health care after a large-scale educational intervention
  26. Evaluation of high resolution gel β2-transferrin for detection of cerebrospinal fluid leak
  27. Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease
  28. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission
  29. Bone mass density selectively correlates with serum markers of oxidative damage in post-menopausal women
  30. Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma
  31. Performance of different screening methods for the determination of urinary glycosaminoclycans
  32. Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnosis tools for digestive non-IgE-mediated cow’s milk allergy in toddlers
  33. An internal validation approach and quality control on hematopoietic chimerism testing after allogeneic hematopoietic cell transplantation
  34. Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors
  35. Cooperation experience in a multicentre study to define the upper limits in a normal population for the diagnostic assessment of the functional lupus anticoagulant assays
  36. Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure
  37. Suitability of POC lactate methods for fetal and perinatal lactate testing: considerations for accuracy, specificity and decision making criteria
  38. Point-of-care testing on admission to the intensive care unit: lactate and glucose independently predict mortality
  39. Reference Values and Biological Variations
  40. CA125 reference values change in male and postmenopausal female subjects
  41. Distributions and ranges of values of blood and urinary biomarker of inflammation and oxidative stress in the workers engaged in office machine manufactures: evaluation of reference values
  42. Cancer Diagnostics
  43. Association of acute phase protein-haptoglobin, and epithelial-mesenchymal transition in buccal cancer: a preliminary report
  44. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients
  45. Evaluation of the BRAHMS Kryptor® Thyroglobulin Minirecovery Test in patients with differentiated thyroid carcinoma
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 16.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2012-0414/html?lang=en
Scroll to top button